Welcome to our dedicated page for Jade Biosciences SEC filings (Ticker: JBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jade Biosciences, Inc. (JBIO) SEC filings page on Stock Titan provides access to the company’s public regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biotechnology company, Jade uses filings such as Forms 8-K, 10-Q, and 10-K to report material events, financial results, and other information related to its autoimmune disease pipeline and corporate activities.
Recent Form 8-K filings describe key transactions and developments, including private placements and PIPE financings, licensing and manufacturing agreements, and corporate changes. For example, the company has reported securities purchase agreements for private placements intended to fund research and development, general corporate expenses, and working capital; a license agreement with Paragon Therapeutics for BAFF-R–targeting antibodies; and a master services agreement with Patheon Biologics LLC for development and cGMP manufacturing of JADE101 and potential future programs.
Other 8-K filings furnish press releases that summarize quarterly financial results, cash runway expectations based on current operating plans, and updates on the clinical and preclinical status of JADE101, JADE201, and an additional undisclosed antibody program. Filings also document corporate events such as executive appointments or departures and the completion of a business combination that resulted in the current Jade Biosciences, Inc. entity and name.
Through this page, users can follow Jade’s periodic and current reports to understand how the company describes its financial condition, capital structure, material agreements, and risk factors over time. Stock Titan enhances access to these documents with AI-powered summaries that help explain the significance of filings, highlight key terms in agreements, and clarify how financing and licensing arrangements relate to the development of JADE101, JADE201, and the broader autoimmune pipeline.
Fairmount Funds Management LLC and related entities reported beneficial ownership of
Insiders and affiliated funds purchased equity in Jade Biosciences (JBIO). On
The filing notes the securities were purchased in a private placement and relies on Rule 16b-3(d)(1) exemption. Fairmount Funds Management LLC is the manager for the two funds, and Tomas Kiselak and Peter Harwin are identified as managers; they disclaim beneficial ownership except for pecuniary interests. The pre-funded warrants have no expiration and include a 9.99% beneficial ownership cap on exercise.
Jade Biosciences, Inc. announced securities and licensing developments related to its BAFF-R candidate, JADE201. The company agreed to issue pre-funded warrants to purchase an aggregate of 1,402,092 shares of common stock at a purchase price of
Under a License Agreement tied to the BAFF-R program, the company paid for an IND-enabling toxicology study in
Jade Biosciences, Inc. (JBIO) filed an 8-K reporting a material employment-related payment arrangement dated September 9, 2025. The filing states the company will make (i) a one-time cash payment equal to 12 months of the executive's current base salary and (ii) a cash payment equal to the COBRA premiums for continuation coverage for a period of 12 months. The disclosure is signed by Tom Frohlich, Chief Executive Officer. The filing provides the specific severance and benefits continuation terms but does not disclose the executive's name beyond the reference to Dr. Kocinsky or the dollar amounts of base salary.
Frazier Life Sciences and affiliated investment vehicles disclosed their beneficial ownership in Jade Biosciences common stock. Frazier Life Sciences Public Fund, L.P. holds 1,340,703 shares (representing 4.2% of the class), Frazier Life Sciences Public Overage Fund, L.P. holds 395,508 shares (1.2%), Frazier Life Sciences X, L.P. holds 11,897 shares (0.0%) and Frazier Life Sciences XI, L.P. holds 24,008 shares (0.1%). The percentages use a base of 32,235,927 shares outstanding disclosed by the issuer. The filing corrects prior attributions of ownership among certain fund managers and states the positions were not acquired to change or influence control of the issuer.
Jade Biosciences reported significant financing activity and operating losses in the quarter ended June 30, 2025. Cash and cash equivalents totaled $220.9 million at June 30, 2025, largely reflecting net proceeds of $190.5 million from the Pre-Closing Financing and cash acquired in the reverse recapitalization. Total assets were $223.97 million. The company recorded a net loss of $32.1 million for the three months and $70.3 million for the six months ended June 30, 2025. Operating expenses were $27.8 million for the quarter, including $22.5 million of research and development and $5.2 million of general and administrative expenses.
Corporate actions included a reverse recapitalization, redomestication to Nevada, conversion of $95.0 million of convertible notes into equity, issuance of Series A non-voting convertible preferred stock, and 32,626,730 shares outstanding as of August 8, 2025. The company stated its $220.9 million of cash is expected to fund operations for at least 12 months. Development programs include lead candidate JADE101 (APRIL) with first-in-human dosing planned in Q3 2025 and interim data expected H1 2026.
Jade Biosciences, Inc. filed a current report to note that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company states that the press release, included as Exhibit 99.1, provides details of these quarterly results.
The company clarifies that the earnings press release and related disclosure are being furnished, not filed, which means they are not subject to certain liability provisions of the securities laws and are not automatically incorporated into other SEC filings.
On July 14, 2025, Jade Biosciences, Inc. (ticker JBIO) filed a Form 4 disclosing that its Chief Financial Officer, Bradford D. Dahms, received a new equity award.
- Security granted: Stock option covering 526,000 shares of common stock.
- Exercise price: $9.00 per share.
- Term: Expires on July 14, 2035 (10-year term).
- Vesting schedule: 25 % vests on July 14, 2026; the remaining 75 % vests in equal monthly installments over the following three years, contingent on continued employment.
- Ownership form: Direct.
No common stock was bought or sold; the filing strictly reports the compensatory option grant. The transaction could increase potential dilution by up to 526,000 shares if fully exercised, but its materiality depends on JBIO’s total shares outstanding, which is not provided in this filing.